Impact of %6 HES 130/0.4 and %4 Gelofusine Infusion on Kidney Function in the Living-donor Liver Transplantation

NCT ID: NCT02079350

Last Updated: 2014-03-05

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 36 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2011-01-31
• Study Completion Date: 2013-12-31

Brief Summary

Although the negative impacts of colloid solutions with high molecular weight on renal functions, combination of lower molecular weight colloid varieties with crystalloid solutions and its use during intraoperative period have been subject to current research. Since the first liver transplantation, pre-or post-transplantation renal problems are still among the main causes of mortality and morbidity. The aim of the study was to evaluate the effects of fluid replacement solutions used intraoperatively on renal functions in elective living-donor liver transplantation.This study was approved by the Ethics Committee of Hospital and all patients were informed and gave written consent. Participants were patients scheduled for elective living-donor liver transplantation. Patients with normal renal function were randomly allocated to infusion with 6% HES 130/0.4 (HES Group) and 4% Gelofusine (GEL Group). Blood samples were obtained before induction of anesthesia (baseline), at the end of the operation, and postoperative days 1 and 4. Different eGFR formulas using creatinine (MDRD, CKD-EPI, and Cockraud Gault) were used to calculate estimated glomerular filtration rates.

Conditions

Patients Undergoing Liver Transplantation

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

%4 Gelofusine

patients administered %4 Gelofusine during liver transplantation

%6 HES and %4 Gelofusine

Intervention Type: DRUG

%6 HES

patients administered %6 HES during liver transplantation

%6 HES and %4 Gelofusine

Intervention Type: DRUG

Interventions

%6 HES and %4 Gelofusine

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

-Normal kidney function

Exclusion Criteria

• anormal kidney function
• cadaveric transplantation
• emergency operation
• patients less than 18 years old

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Turkiye Yuksek Ihtisas Education and Research Hospital

OTHER_GOV

Sponsor Role: lead

Responsible Party

aslı demir

Associated professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Turkey Yuksek Ihtisas Education and Research Hospital, Anesthesiology Clinic

Ankara, , Turkey (Türkiye)

Countries

Turkey (Türkiye)

Other Identifiers

11739

Identifier Type: -

Identifier Source: org_study_id